Developer docs
API playgroundTry for free, no card

Search company profiles

Verity Pharmaceuticals

Full company profile

uuid0009pis

Namestring
Verity Pharmaceuticals
Legal namestring
Verity Pharmaceuticals, Inc.
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, pharmaceutical commercialization, urology therapeutics, oncology treatments, infectious disease drugs
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Licensing and Commercialization
TypeLicensing Royalties
Description

Verity Pharma generates revenue through exclusive licensing agreements to commercialize pharmaceutical products in specified territories. The company receives commercial rights to products from partners and generates revenue through product sales and commercialization activities. In January 2024, Lipocine and Verity entered into an exclusive license agreement where Verity gained commercial rights to TLANDO in the US and Canada, with Lipocine receiving license fee payments.

2Product Promotion Services
TypeProfessional Services
Description

Verity provides promotional services for pharmaceutical products in exchange for revenue sharing or promotional fees. The company promotes products from partners (such as Akynzeo, Valchlor from Helsinn, Natesto from Acerus) in specific markets like Puerto Rico, leveraging its existing commercial footprint and healthcare network while partners maintain control of distribution, market access, and regulatory activities.

veritypharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Verity Pharmaceuticals commercializes specialty prescription pharmaceuticals in urology, oncology, infectious disease, and men's/women's health across the US, Canada, and Puerto Rico. The company in-licenses or acquires late-stage/in-market pharmaceutical products from global manufacturers and commercializes them through a focused direct sales force targeting healthcare providers. Core products include TLANDO (oral testosterone), TRELSTAR (prostate cancer), VERITY-BCG (bladder cancer), Zeulide Depot, and IVOZFO, with additional promotional partnerships in Puerto Rico.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • VERITY-BCG resolved Canada's multi-year BCG drug shortage, making Canada the first country in the western world to solve the shortage crisis
+2 more records
Product overview1 text field

Verity Pharmaceuticals is a specialty pharmaceutical company that commercializes prescription therapeutics through licensing and distribution partnerships. The company operates across three geographic markets (U.S., Canada, and Puerto Rico) and focuses on therapeutic areas including urology, oncology, infectious disease, and men's/women's health. The product portfolio includes proprietary brands (TLANDO, TRELSTAR, VERITY-BCG, Zeulide Depot, IVOZFO) as well as partnered brands promoted in Puerto Rico (AKYNZEO, VALCHLOR, NATESTO, VIBATIV). The company does not develop drugs internally but acquires late-stage or in-market products from global pharmaceutical partners and commercializes them through its established infrastructure.

Product and service9 records
1TLANDO
CategoryMen's Health / Testosterone Replacement Therapy
Description

Oral testosterone replacement therapy (TRT) approved for adult males with conditions associated with deficiency or absence of endogenous testosterone, including primary and hypogonadotropic hypogonadism. Developed using Lipocine's proprietary Lip'ral drug delivery technology platform. Commercialized by Verity in the US and Canada under exclusive license.

2TRELSTAR
CategoryOncology / Prostate Cancer Treatment
Description

Gonadotropin-releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer. Available in 1, 3, and 6-month sustained-release formulations. Commercialized by Verity in the US under exclusive 20-year extendable agreement with Debiopharm.

3VERITY-BCG
CategoryUrology / Bladder Cancer Treatment
Description

Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer. Adjuvant therapy after transurethral resection of non-muscle-invasive bladder cancer. Manufactured by Serum Institute of India and commercialized by Verity in Canada.

4Zeulide Depot
CategoryOncology / Prostate Cancer Treatment
Description

Leuprolide acetate for depot suspension, a Luteinizing Hormone-Releasing Hormone (LHRH) analog indicated for the palliative treatment of advanced and/or metastatic prostate cancer. Uses patented microsphere technology for sustained release. Commercialized by Verity in Canada.

5IVOZFO
CategoryInfectious Disease / Hospital Antibiotics
Description

Intravenous fosfomycin injection, a first-in-class IV antibiotic with broad spectrum bactericidal activity against Gram-negative and Gram-positive organisms including MDR strains. Indicated for complicated urinary tract infections, osteomyelitis, bacterial meningitis, bacteremia, and nosocomial lower respiratory tract infections. Licensed from InfectoPharm and commercialized in Canadian hospital market.

6AKYNZEO
CategoryOncology Supportive Care
Description

Fixed combination of 5-HT3 and NK1 receptor antagonists (netupitant/palonosetron) approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. Available in oral capsule and injectable formulations. Promoted by Verity in Puerto Rico through partnership with Helsinn Therapeutics.

7VALCHLOR
CategoryOncology / Cutaneous T-Cell Lymphoma
Description

Topical mechlorethamine gel (0.016%) indicated for the treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. Promoted by Verity in Puerto Rico through partnership with Helsinn Therapeutics.

8NATESTO
CategoryMen's Health / Testosterone Replacement Therapy
Description

Testosterone nasal gel for testosterone replacement therapy. Promoted by Verity in Puerto Rico through commercial agreement with Acerus Pharmaceuticals, leveraging Verity's existing commercial footprint and healthcare network.

9VIBATIV
CategoryInfectious Disease / Hospital Antibiotics
Description

FDA-approved injectable anti-infective (telavancin) designed to treat serious infections including hospital-acquired and ventilator-associated pneumonia, including those from MRSA. Promoted by Verity in Puerto Rico through partnership with Cumberland Pharmaceuticals.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

In January 2024, Lipocine and Verity Pharma entered into an exclusive license agreement under which Verity Pharma gained commercial rights to TLANDO (testosterone replacement therapy) in the United States and Canada. TLANDO is the first and only oral TRT option approved by the FDA that does not require dose titration. Commercialization was transitioned to Verity Pharma effective February 1, 2024. Lipocine received an $11 million license fee with tranches of $5M (received), $2.5M (due January 2025), and $1M (due January 2026). Verity Pharma filed an NDS for TLANDO in Canada in June 2025.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-03-14
Description

Cumberland Pharmaceuticals and Verity Pharmaceuticals announced the launch of VIBATIV (telavancin) injection in Puerto Rico. Cumberland is responsible for product supply while Verity commercializes and promotes the product in the local market. VIBATIV is an FDA-approved injectable anti-infective designed to treat serious infections including hospital-acquired and ventilator-associated pneumonia, including those from MRSA.

3Helsinn Therapeutics
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-02-16
Description

Verity Pharmaceuticals and Helsinn Therapeutics signed an exclusive agreement for the promotion of Akynzeo (netupitant/palonosetron) and Valchlor (mechlorethamine gel) in Puerto Rico. Akynzeo is the first and only 5-HT3 and NK1 receptor antagonists fixed combination for chemotherapy-induced nausea and vomiting prevention. Valchlor is indicated for topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.

veritypharma.com
4Acerus Pharmaceuticals
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-10
Description

Verity Pharmaceuticals formed a commercial agreement with Acerus Pharmaceuticals for exclusive rights to promote Natesto (testosterone nasal gel) in Puerto Rico. Verity promotes Natesto to healthcare professionals throughout Puerto Rico leveraging its existing commercial footprint and healthcare network. Acerus maintains control of distribution, market access, and regulatory activities on the island.

veritypharma.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-09-09
Description

Verity partnered with Serum Institute of India (SIIPL), the world's largest manufacturer of vaccines, for the manufacturing and supply of VERITY-BCG (Bacillus Calmette-Guérin) for bladder cancer treatment. SIIPL manufactures BCG and supplies finished product to Verity, which markets and distributes in Canada. This partnership resolved Canada's multi-year BCG drug shortage, making Canada the first country in the western world to solve the crisis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-09
Description

Debiopharm partnered with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar (triptorelin pamoate), a hormone therapy for prostate cancer. The agreement grants Verity Pharmaceuticals rights to commercialize Trelstar in a 20-year, extendable agreement. Trelstar is indicated for the palliative treatment of advanced prostate cancer and is a gonadotropin-releasing hormone (GnRH) agonist that works by decreasing testosterone levels.

7Vygoris
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-11-01
Description

Verity entered into an exclusive Canadian licensing and supply agreement with Vygoris Ltd. (London, UK), a subsidiary of French specialist generics company Substipharm, for the supply of Mitomycin for the Canadian pharmaceutical market. Vygoris supplies the finished product and Verity markets and distributes. Mitomycin is used primarily to treat bladder cancer as well as some types of colon and stomach cancer.

veritypharma.com
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2018-03-21
Description

Verity entered into an exclusive Canadian licensing agreement with InfectoPharm (InfectoPharm Arzneimittel und Consilium GmbH) for the introduction of Intravenous Fosfomycin for the Canadian hospital market. InfectoPharm supplies the finished product while Verity markets and distributes. IVOZFO was granted priority review status by Health Canada and received Notice of Compliance in May 2019.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

PendoPharm (division of Pharmascience Inc.) divested its rights to commercialize Zeulide Depot to Verity Pharmaceuticals. Under the agreement, Verity markets and sells Zeulide Depot (Leuprolide acetate for depot suspension) to the Canadian healthcare community. GP Pharm of Barcelona, Spain is the manufacturer of the product.

10GP Pharm
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing Partner
Description

GP Pharm of Barcelona, Spain is the owner and manufacturer of Zeulide Depot. The company specializes in injectable peptide-based products within oncology and urology using microsphere and liposome-based technological platforms for controlled depot delivery. GP Pharm developed the product from R&D through clinical studies, registration, and launch.

veritypharma.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Acerus Pharmaceuticals
TypeDirect peer
Description

Canadian specialty pharma focused on men's health (Natesto nasal testosterone gel), which Verity also promotes in Puerto Rico. Acerus competes with Verity in TRT and shares the same asset-light commercialization model targeting North American markets.

TypeDirect peer
Description

US specialty pharma that partnered with Verity for VIBATIV in Puerto Rico. Cumberland markets branded specialty hospital products through a similar lean commercial model, making it a close structural comparable.

TypeDirect peer
Description

US specialty pharma that licenses TLANDO oral TRT to Verity. Lipocine focuses on men's health using proprietary drug delivery technology, sharing both therapeutic-area focus and partner-based commercialization with Verity.

TypeDirect peer
Description

Swiss/US specialty pharma that partners with Verity for Akynzeo and Valchlor promotion in Puerto Rico. Helsinn focuses on oncology and supportive care specialty pharma, mirroring Verity's therapeutic mix and licensing-driven go-to-market approach.

TypeDirect peer
Description

Canadian specialty pharma focused on women's health and specialty therapeutics. Duchesnay's Canadian base, specialty-pharma focus, and emphasis on underserved therapeutic areas align closely with Verity's Canadian heritage and specialty positioning.

TypeDirect peer
Description

Swiss specialty pharma that granted Verity 20-year exclusive US rights to Trelstar for prostate cancer. Debiopharm develops and out-licenses specialty therapeutics, sharing Verity's urology and oncology focus through a partner-based commercialization model.

TypeDirect peer
Description

US specialty pharma focused on urology and oncology (including prostate cancer treatments). Tolmar competes directly with Verity's Trelstar and Zeulide Depot in urology, serving the same urologist/oncologist customer base.

TypeBroad incumbent
Description

Large diversified specialty pharma with broad urology, oncology, and specialty therapeutics portfolios across North America. Operates as a broad incumbent with overlapping products and the same customer segments as Verity, but at much larger scale.

9Endo International
TypeBroad incumbent
Description

Large specialty pharma with urology and men's health franchises (including testosterone products). Endo's specialty division competes with Verity's TRT and urology products while offering a much broader portfolio.

TypeBroad incumbent
Description

Global specialty pharma with strong urology and reproductive health franchises. Ferring's focus on urology, prostate cancer, and specialty therapeutics overlaps with Verity's portfolio and is a potential partner or competitor for in-licensed products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Verity Pharmaceuticals

Specialty Pharmaceuticalsveritypharma.com

Verity Pharmaceuticals firmographics

Firmographics
Name
Verity Pharmaceuticals
Legal name
Verity Pharmaceuticals, Inc.
Website
https://veritypharma.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Verity Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Pharmaceutical commercialization
  • Urology therapeutics
  • Oncology treatments
  • Infectious disease drugs

Where Verity Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Verity Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

  1. Product Licensing and Commercialization: Verity Pharma generates revenue through exclusive licensing agreements to commercialize pharmaceutical products in specified territories. The company receives commercial rights to products from partners and generates revenue through product sales and commercialization activities. In January 2024, Lipocine and Verity entered into an exclusive license agreement where Verity gained commercial rights to TLANDO in the US and Canada, with Lipocine receiving license fee payments.
  2. Product Promotion Services: Verity provides promotional services for pharmaceutical products in exchange for revenue sharing or promotional fees. The company promotes products from partners (such as Akynzeo, Valchlor from Helsinn, Natesto from Acerus) in specific markets like Puerto Rico, leveraging its existing commercial footprint and healthcare network while partners maintain control of distribution, market access, and regulatory activities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Verity Pharmaceuticals product offering

Product offering

Core offering

Verity Pharmaceuticals commercializes specialty prescription pharmaceuticals in urology, oncology, infectious disease, and men's/women's health across the US, Canada, and Puerto Rico. The company in-licenses or acquires late-stage/in-market pharmaceutical products from global manufacturers and commercializes them through a focused direct sales force targeting healthcare providers. Core products include TLANDO (oral testosterone), TRELSTAR (prostate cancer), VERITY-BCG (bladder cancer), Zeulide Depot, and IVOZFO, with additional promotional partnerships in Puerto Rico.

Product overview

Verity Pharmaceuticals is a specialty pharmaceutical company that commercializes prescription therapeutics through licensing and distribution partnerships. The company operates across three geographic markets (U.S., Canada, and Puerto Rico) and focuses on therapeutic areas including urology, oncology, infectious disease, and men's/women's health. The product portfolio includes proprietary brands (TLANDO, TRELSTAR, VERITY-BCG, Zeulide Depot, IVOZFO) as well as partnered brands promoted in Puerto Rico (AKYNZEO, VALCHLOR, NATESTO, VIBATIV). The company does not develop drugs internally but acquires late-stage or in-market products from global pharmaceutical partners and commercializes them through its established infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

  • TLANDO Oral testosterone replacement therapy (TRT) approved for adult males with conditions associated with deficiency or absence of endogenous testosterone, including primary and hypogonadotropic hypogonadism. Developed using Lipocine's proprietary Lip'ral drug delivery technology platform. Commercialized by Verity in the US and Canada under exclusive license.
  • TRELSTAR Gonadotropin-releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer. Available in 1, 3, and 6-month sustained-release formulations. Commercialized by Verity in the US under exclusive 20-year extendable agreement with Debiopharm.
  • VERITY-BCG Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer. Adjuvant therapy after transurethral resection of non-muscle-invasive bladder cancer. Manufactured by Serum Institute of India and commercialized by Verity in Canada.
  • Zeulide Depot Leuprolide acetate for depot suspension, a Luteinizing Hormone-Releasing Hormone (LHRH) analog indicated for the palliative treatment of advanced and/or metastatic prostate cancer. Uses patented microsphere technology for sustained release. Commercialized by Verity in Canada.
  • IVOZFO Intravenous fosfomycin injection, a first-in-class IV antibiotic with broad spectrum bactericidal activity against Gram-negative and Gram-positive organisms including MDR strains. Indicated for complicated urinary tract infections, osteomyelitis, bacterial meningitis, bacteremia, and nosocomial lower respiratory tract infections. Licensed from InfectoPharm and commercialized in Canadian hospital market.
  • AKYNZEO Fixed combination of 5-HT3 and NK1 receptor antagonists (netupitant/palonosetron) approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. Available in oral capsule and injectable formulations. Promoted by Verity in Puerto Rico through partnership with Helsinn Therapeutics.
  • VALCHLOR Topical mechlorethamine gel (0.016%) indicated for the treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. Promoted by Verity in Puerto Rico through partnership with Helsinn Therapeutics.
  • NATESTO Testosterone nasal gel for testosterone replacement therapy. Promoted by Verity in Puerto Rico through commercial agreement with Acerus Pharmaceuticals, leveraging Verity's existing commercial footprint and healthcare network.
  • VIBATIV FDA-approved injectable anti-infective (telavancin) designed to treat serious infections including hospital-acquired and ventilator-associated pneumonia, including those from MRSA. Promoted by Verity in Puerto Rico through partnership with Cumberland Pharmaceuticals.

Quantifiable outcome

  • VERITY-BCG resolved Canada's multi-year BCG drug shortage, making Canada the first country in the western world to solve the shortage crisis
  • +2 more outcomes

Companies that use Verity Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Verity Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Verity Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, minor and major.

  • LipocinecoreStrategic or Co-development Partner · 1 January 2024In January 2024, Lipocine and Verity Pharma entered into an exclusive license agreement under which Verity Pharma gained commercial rights to TLANDO (testosterone replacement therapy) in the United States and Canada. TLANDO is the first and only oral TRT option approved by the FDA that does not require dose titration. Commercialization was transitioned to Verity Pharma effective February 1, 2024. Lipocine received an $11 million license fee with tranches of $5M (received), $2.5M (due January 2025), and $1M (due January 2026). Verity Pharma filed an NDS for TLANDO in Canada in June 2025.
  • Cumberland PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 14 March 2022Cumberland Pharmaceuticals and Verity Pharmaceuticals announced the launch of VIBATIV (telavancin) injection in Puerto Rico. Cumberland is responsible for product supply while Verity commercializes and promotes the product in the local market. VIBATIV is an FDA-approved injectable anti-infective designed to treat serious infections including hospital-acquired and ventilator-associated pneumonia, including those from MRSA.
  • Helsinn TherapeuticsminorChannel Partner/ Reseller/ Distributor · 16 February 2022Verity Pharmaceuticals and Helsinn Therapeutics signed an exclusive agreement for the promotion of Akynzeo (netupitant/palonosetron) and Valchlor (mechlorethamine gel) in Puerto Rico. Akynzeo is the first and only 5-HT3 and NK1 receptor antagonists fixed combination for chemotherapy-induced nausea and vomiting prevention. Valchlor is indicated for topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
  • Acerus PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 10 January 2022Verity Pharmaceuticals formed a commercial agreement with Acerus Pharmaceuticals for exclusive rights to promote Natesto (testosterone nasal gel) in Puerto Rico. Verity promotes Natesto to healthcare professionals throughout Puerto Rico leveraging its existing commercial footprint and healthcare network. Acerus maintains control of distribution, market access, and regulatory activities on the island.
  • Serum Institute of IndiacoreOEM/ Whitelabel/ Licensing Partner · 9 September 2021Verity partnered with Serum Institute of India (SIIPL), the world's largest manufacturer of vaccines, for the manufacturing and supply of VERITY-BCG (Bacillus Calmette-Guérin) for bladder cancer treatment. SIIPL manufactures BCG and supplies finished product to Verity, which markets and distributes in Canada. This partnership resolved Canada's multi-year BCG drug shortage, making Canada the first country in the western world to solve the crisis.
  • DebiopharmcoreStrategic or Co-development Partner · 9 June 2020Debiopharm partnered with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar (triptorelin pamoate), a hormone therapy for prostate cancer. The agreement grants Verity Pharmaceuticals rights to commercialize Trelstar in a 20-year, extendable agreement. Trelstar is indicated for the palliative treatment of advanced prostate cancer and is a gonadotropin-releasing hormone (GnRH) agonist that works by decreasing testosterone levels.
  • VygorisminorOEM/ Whitelabel/ Licensing Partner · 1 November 2018Verity entered into an exclusive Canadian licensing and supply agreement with Vygoris Ltd. (London, UK), a subsidiary of French specialist generics company Substipharm, for the supply of Mitomycin for the Canadian pharmaceutical market. Vygoris supplies the finished product and Verity markets and distributes. Mitomycin is used primarily to treat bladder cancer as well as some types of colon and stomach cancer.
  • InfectoPharmmajorOEM/ Whitelabel/ Licensing Partner · 21 March 2018Verity entered into an exclusive Canadian licensing agreement with InfectoPharm (InfectoPharm Arzneimittel und Consilium GmbH) for the introduction of Intravenous Fosfomycin for the Canadian hospital market. InfectoPharm supplies the finished product while Verity markets and distributes. IVOZFO was granted priority review status by Health Canada and received Notice of Compliance in May 2019.
  • PendoPharmmajorChannel Partner/ Reseller/ DistributorPendoPharm (division of Pharmascience Inc.) divested its rights to commercialize Zeulide Depot to Verity Pharmaceuticals. Under the agreement, Verity markets and sells Zeulide Depot (Leuprolide acetate for depot suspension) to the Canadian healthcare community. GP Pharm of Barcelona, Spain is the manufacturer of the product.
  • GP PharmmajorOEM/ Whitelabel/ Licensing PartnerGP Pharm of Barcelona, Spain is the owner and manufacturer of Zeulide Depot. The company specializes in injectable peptide-based products within oncology and urology using microsphere and liposome-based technological platforms for controlled depot delivery. GP Pharm developed the product from R&D through clinical studies, registration, and launch.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Verity Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Acerus Pharmaceuticals: Canadian specialty pharma focused on men's health (Natesto nasal testosterone gel), which Verity also promotes in Puerto Rico. Acerus competes with Verity in TRT and shares the same asset-light commercialization model targeting North American markets.
  • Cumberland Pharmaceuticals: US specialty pharma that partnered with Verity for VIBATIV in Puerto Rico. Cumberland markets branded specialty hospital products through a similar lean commercial model, making it a close structural comparable.
  • Lipocine: US specialty pharma that licenses TLANDO oral TRT to Verity. Lipocine focuses on men's health using proprietary drug delivery technology, sharing both therapeutic-area focus and partner-based commercialization with Verity.
  • Helsinn Therapeutics: Swiss/US specialty pharma that partners with Verity for Akynzeo and Valchlor promotion in Puerto Rico. Helsinn focuses on oncology and supportive care specialty pharma, mirroring Verity's therapeutic mix and licensing-driven go-to-market approach.
  • Duchesnay Inc. Canadian specialty pharma focused on women's health and specialty therapeutics. Duchesnay's Canadian base, specialty-pharma focus, and emphasis on underserved therapeutic areas align closely with Verity's Canadian heritage and specialty positioning.
  • Debiopharm: Swiss specialty pharma that granted Verity 20-year exclusive US rights to Trelstar for prostate cancer. Debiopharm develops and out-licenses specialty therapeutics, sharing Verity's urology and oncology focus through a partner-based commercialization model.
  • Tolmar Pharmaceuticals: US specialty pharma focused on urology and oncology (including prostate cancer treatments). Tolmar competes directly with Verity's Trelstar and Zeulide Depot in urology, serving the same urologist/oncologist customer base.

Broad incumbents

  • Bausch Health Companies: Large diversified specialty pharma with broad urology, oncology, and specialty therapeutics portfolios across North America. Operates as a broad incumbent with overlapping products and the same customer segments as Verity, but at much larger scale.
  • Endo International: Large specialty pharma with urology and men's health franchises (including testosterone products). Endo's specialty division competes with Verity's TRT and urology products while offering a much broader portfolio.
  • Ferring Pharmaceuticals: Global specialty pharma with strong urology and reproductive health franchises. Ferring's focus on urology, prostate cancer, and specialty therapeutics overlaps with Verity's portfolio and is a potential partner or competitor for in-licensed products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Verity Pharmaceuticals social profiles

Digital presence

Verity Pharmaceuticals compliance and trust

Trust signal

Compliance2 records

Verity Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Verity Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles10 records

Verity Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Verity Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verity Pharmaceuticals

What does Verity Pharmaceuticals do?

Verity Pharmaceuticals commercializes specialty prescription pharmaceuticals in urology, oncology, infectious disease, and men's/women's health across the US, Canada, and Puerto Rico. The company in-licenses or acquires late-stage/in-market pharmaceutical products from global manufacturers and commercializes them through a focused direct sales force targeting healthcare providers. Core products include TLANDO (oral testosterone), TRELSTAR (prostate cancer), VERITY-BCG (bladder cancer), Zeulide Depot, and IVOZFO, with additional promotional partnerships in Puerto Rico.

Is Verity Pharmaceuticals a public or private company?

Verity Pharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Verity Pharmaceuticals founded?

Verity Pharmaceuticals was founded in 2016. It employs 51 to 100 people.

Where is Verity Pharmaceuticals based?

Verity Pharmaceuticals is headquartered in Mississauga, Canada, in the North America region.

How does Verity Pharmaceuticals make money?

Two revenue lines are on record. Product Licensing and Commercialization is the primary driver. The others are product Promotion Services.

Who are Verity Pharmaceuticals's main competitors?

Direct peers on record are Acerus Pharmaceuticals, Cumberland Pharmaceuticals, Lipocine, Helsinn Therapeutics, Duchesnay Inc., Debiopharm and Tolmar Pharmaceuticals. Broad incumbents are Bausch Health Companies, Endo International and Ferring Pharmaceuticals.

Does Verity Pharmaceuticals have an API?

No public API is recorded for Verity Pharmaceuticals.

What industry is Verity Pharmaceuticals in?

Verity Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLipocine Announces Financial Results for the Third Quarter Ended September 30, 2025Lipocine Inc. reported a net loss of $3.2 million for Q3 2025, compared to a $2.2 million loss in Q3 2024, while its cash position declined to $15.1 million from $21.6 million at year-end 2024. The company continues enrolling patients in its Phase 3 trial for LPCN 1154, an oral treatment for postpartum depression, with topline data expected in Q2 2026 and a 505(b)(2) NDA submission planned for that year. Nine-month revenue dropped significantly to $831,000 from $7.7 million in the prior year period, primarily due to a $7 million licensing payment received in 2024 from Verity Pharma for TLANDO rights.PR NewswireLipocine Announces Financial Results for the First Quarter Ended March 31, 2024Lipocine Inc. reported net income of $3.5 million for Q1 2024, a significant improvement from a net loss of $3.9 million in Q1 2023, with revenue of $7.6 million driven primarily by a $7.5 million license fee from Verity Pharma. The company announced positive clinical developments across three pipeline candidates: completion of dosing for LPCN 1154 in postpartum depression, positive 52-week results for LPCN 1148 in cirrhosis management, and positive Phase 2 results for LPCN 2401 in obesity management. Lipocine entered into an exclusive license agreement with Verity Pharma in January 2024 for TLANDO marketing rights in the US and Canada, potentially worth up to $270 million including license fees, milestones, and royalties.PR NewswireLipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsLipocine announced that commercialization of TLANDO in the U.S. has been transitioned to Verity Pharma, effective February 1, 2024. Lipocine received the second tranche of the $11 million license fee, $5 million, with additional payments due in 2025 and 2026.PR NewswireCumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®Cumberland Pharmaceuticals announced a co-promotion agreement with Verity Pharmaceuticals to feature Sancuso across the U.S. through Verity's oncology sales organization. Sancuso is the first FDA-approved patch for preventing chemotherapy-induced nausea and vomiting, and the companies will share in the incremental contribution margin.GlobeNewswireVerity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto RicoVerity Pharmaceuticals and Helsinn Therapeutics signed an agreement granting Verity exclusive rights to promote Akynzeo and Valchlor in Puerto Rico. Helsinn retains control of distribution, market access, and regulatory activities. The products target cancer supportive care and chemotherapy-induced nausea.GlobeNewswireAcerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto RicoAcerus Pharmaceuticals signed an agreement with Verity Pharmaceuticals for exclusive promotion of NATESTO in Puerto Rico, with Verity to begin promoting in Q1 2022. Acerus retains control of distribution, market access, and regulatory activities on the island.PR NewswireDebiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate CancerDebiopharm, a Swiss biopharmaceutical company, and Verity Pharmaceuticals Inc., a US specialty pharmaceutical company focused on genitourinary diseases, announced an exclusive agreement granting Verity Pharmaceuticals the rights to commercialize Trelstar\u00ae (triptorelin pamoate) for prostate cancer treatment in the United States. The 20-year extendable agreement leverages Verity Pharma's uro-oncology expertise to relaunch the hormone therapy brand, which was first approved in the US in 2000 for palliative treatment of hormone-dependent advanced prostate cancer. Trelstar\u00ae works as an androgen deprivation therapy by maintaining testosterone levels below castration levels, helping delay progression to castrate-resistant prostate cancer.